Search

everythinglearnresearchcommunity

for

Search:↓

The user experienced positive scalp results with Dutasteride but noticed beard thinning, prompting a switch back to Finasteride. They plan to monitor the situation and may consider combining treatments in the future.

Low-dose topical finasteride may reduce scalp DHT with fewer side effects than oral finasteride, though it can still lower blood serum DHT. Users report varying experiences, with some finding topical use effective and side-effect-free, while others note significant DHT suppression.

OP struggles with scalp flakes causing hair loss and has tried Selsun Blue, Ketoconazole, and ZPT Shampoo without success. Suggestions include using salicylic acid shampoo, shaving the head, using Nizoral, and combining treatments like Minoxidil and finasteride.

Topical dutasteride may be effective for hair loss by staying in the scalp and minimizing bloodstream absorption, potentially improving hair results and reducing side effects. The user seeks advice on its effectiveness.

User noticed scalp showing at 26, started finasteride at 28, and saw hair improvement by 30. Others shared similar experiences and advised trusting personal observations and trying finasteride early to prevent further hair loss.

Hair thinning/loss associated with burning scalp pain. Finasteride helped relieve "DHT itch" for one person.

Individuals with oily scalps, dandruff, and diffuse thinning hair loss who have managed to either halt the loss or regrow their hair by using topical finasteride and minoxidil as well as microneedling and ketoconazole 2% shampoo.

New potential hair loss treatment uses molecules from hairy moles to stimulate follicle growth. Topical solution requires less frequent application, like Botox injections a few times per year.

A 32-year-old male with hair loss cannot use finasteride due to erectile dysfunction and minoxidil due to scalp psoriasis. He seeks alternative treatments for his condition.

Exploring the idea of using facial hair properties for scalp regeneration in male pattern baldness, considering the potential of transferring androgen-resistant characteristics from facial hair to the scalp. Challenges include complexity, scalability, aesthetics, and safety, but the concept encourages innovative thinking beyond current treatments like Minoxidil, Finasteride, and hair transplants.

Oral Dutasteride and topical Finasteride may have similar effects on scalp DHT, but topical Dutasteride might be less effective due to poor absorption. Combining oral Dutasteride with topical Finasteride could potentially enhance results by blocking DHT in both the scalp and serum.

Epristeride is a selective 5 alpha reductase type 2 inhibitor that may reduce scalp DHT similarly to finasteride, with potentially fewer side effects. It is suggested that combining epristeride with finasteride or dutasteride could enhance hair loss treatment effectiveness.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

The post and conversation discuss the link between DHT (a hormone), scalp itchiness, and hair loss. Some users share their experiences and treatments, including the use of fluconazole, corticosteroids, and ketoconazole shampoo, with one user suspecting minoxidil as a potential cause of their symptoms.

Why androgenic alopecia affects the scalp rather than other body parts, potential explanations for this phenomenon, treatments available to combat hair loss, and the implications of male attractiveness in modern society.

PP405 shows potential for hair growth by increasing terminal hair and converting vellus hairs, but results are modest and more waiting is needed. It complements existing treatments like minoxidil and finasteride, but won't replace them.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

A user shared their progress with hair loss treatment using 0.1% topical finasteride for 5 months and 6% minoxidil for 2 months, reporting reduced hair shedding, less scalp visibility, and healthier hair. They experienced no significant side effects except initial itching and dandruff, and noted an increase in libido.

A 42-year-old had 2,100 grafts transplanted to the frontal third of the scalp, using treatments like Dutasteride, oral Minoxidil, ketoconazole shampoo, dermarolling, and PRP. They plan to add RU58841 and have scheduled SMP to improve cosmetic results.

The conversation discusses the need for a localized 5-alpha reductase inhibitor that only affects the scalp without systemic side effects, similar to pyrilutamide's approach. Current treatments like topical liposomal finasteride and dutasteride are mentioned, but concerns about their systemic effects and lack of research are highlighted.

Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hair follicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.

Topical finasteride that doesn't penetrate the skin could potentially treat hair loss without side effects. Current challenges include finding a formulation that remains on the scalp without increasing blood levels.

The conversation discusses the potential benefits of creating a hydrophobic version of finasteride to reduce systemic side effects while maintaining scalp health. It compares this idea to fluridil, which is designed to be hydrophobic and has less systemic absorption.

Switching from topical to oral minoxidil due to scalp irritation and unsatisfactory results, while also seeking cheaper options in the U.S. Oral minoxidil is generally favored for its effectiveness and fewer application downsides, with CostPlusDrugs and GoodRx offering affordable prices.

The conversation discusses hair loss treatments including oral minoxidil 5mg, dutasteride 1mg, and suggestions to use a derma stamp on the scalp. Some users believe these treatments can improve hair condition or at least stabilize loss, while one suggests considering a hair transplant after a year if desired.

The conversation is about using topical Dutasteride for hair loss. One tip given is to apply it to the scalp.

Hair loss may be caused by calcification of capillaries in the scalp, restricting blood flow to hair follicles. A daily treatment regimen including high doses of Vitamins D and K, Magnesium, and Nattokinase could potentially decalcify these capillaries, improving blood flow and hair growth. However, some users warn against excessive Vitamin D intake and emphasize the need for medical consultation.

The post discusses the difference in effects of Minoxidil (Min) on scalp and facial hair. The user questions why Min-induced hair growth on the scalp is temporary, while facial hair growth seems permanent, even after stopping Min. They propose theories, including different Min mechanisms on body and facial hair, the role of DHT, and the possibility of not achieving fully terminal hair. The responses include personal experiences and theories about Min's effects on hair growth.

The post and conversation discuss different methods of applying hair loss treatments directly to the scalp. The original poster suggests using a 1ml TB Syringe & Ophthalmic Cannula for precise application, while others share their own methods, including sprays, droppers, and simple syringes.

New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.